Roland Seiler
YOU?
Author Swipe
View article: Supplementary Figure S7 from Molecular Characterization of Residual Muscle-Invasive Bladder Cancer Identifies a Scar-Like Transcriptomic Profile with Favorable Prognosis after Neoadjuvant Therapy
Supplementary Figure S7 from Molecular Characterization of Residual Muscle-Invasive Bladder Cancer Identifies a Scar-Like Transcriptomic Profile with Favorable Prognosis after Neoadjuvant Therapy Open
Figure S7. ESTIMATE tumor purity scores for the ABACUS cohort, stratified by LumP, LumNS, LumU, Basal-Sq, NE-like, and Stroma-rich vs Scar-like and the former tumor bed.
View article: Data from Molecular Characterization of Residual Muscle-Invasive Bladder Cancer Identifies a Scar-Like Transcriptomic Profile with Favorable Prognosis after Neoadjuvant Therapy
Data from Molecular Characterization of Residual Muscle-Invasive Bladder Cancer Identifies a Scar-Like Transcriptomic Profile with Favorable Prognosis after Neoadjuvant Therapy Open
Purpose:Many patients have residual disease after neoadjuvant therapy, but their prognosis and need for adjuvant therapy are unclear. This study evaluates patient prognosis based on the molecular profiling of residual disease at cystectomy…
View article: Supplementary Figure S6 from Molecular Characterization of Residual Muscle-Invasive Bladder Cancer Identifies a Scar-Like Transcriptomic Profile with Favorable Prognosis after Neoadjuvant Therapy
Supplementary Figure S6 from Molecular Characterization of Residual Muscle-Invasive Bladder Cancer Identifies a Scar-Like Transcriptomic Profile with Favorable Prognosis after Neoadjuvant Therapy Open
Figure S6. Kapplan-Meier curves comparing disease free survival outcomes for Consensus stroma-rich tumors within the post-NAC cohort (Log-Rank P = 0.27).
View article: Supplementary Figure S4 from Molecular Characterization of Residual Muscle-Invasive Bladder Cancer Identifies a Scar-Like Transcriptomic Profile with Favorable Prognosis after Neoadjuvant Therapy
Supplementary Figure S4 from Molecular Characterization of Residual Muscle-Invasive Bladder Cancer Identifies a Scar-Like Transcriptomic Profile with Favorable Prognosis after Neoadjuvant Therapy Open
Figure S4. Twelve of the thirteen 13 scar-like cases previously identified in pembrolizumab-treated tumors (panel A) classified as stroma-rich by the consensus subtyping model, representing a subgroup with improved clinical outcomes (panel…
View article: Supplementary Figure S5 from Molecular Characterization of Residual Muscle-Invasive Bladder Cancer Identifies a Scar-Like Transcriptomic Profile with Favorable Prognosis after Neoadjuvant Therapy
Supplementary Figure S5 from Molecular Characterization of Residual Muscle-Invasive Bladder Cancer Identifies a Scar-Like Transcriptomic Profile with Favorable Prognosis after Neoadjuvant Therapy Open
Figure S5. Differential gene expression analysis comparing the CC-scar-like to the remaining Consensus stroma-rich tumors. Select downregulated genes have been circled in blue.
View article: Supplementary Figure S9 from Molecular Characterization of Residual Muscle-Invasive Bladder Cancer Identifies a Scar-Like Transcriptomic Profile with Favorable Prognosis after Neoadjuvant Therapy
Supplementary Figure S9 from Molecular Characterization of Residual Muscle-Invasive Bladder Cancer Identifies a Scar-Like Transcriptomic Profile with Favorable Prognosis after Neoadjuvant Therapy Open
Figure S9: Gene expression of select cancer-associated markers located on chromosomes frequently altered in muscle-invasive bladder cancer.
View article: Supplementary Table S2 from Molecular Characterization of Residual Muscle-Invasive Bladder Cancer Identifies a Scar-Like Transcriptomic Profile with Favorable Prognosis after Neoadjuvant Therapy
Supplementary Table S2 from Molecular Characterization of Residual Muscle-Invasive Bladder Cancer Identifies a Scar-Like Transcriptomic Profile with Favorable Prognosis after Neoadjuvant Therapy Open
Table S2: Clinical, pathological tumor- and pathological node status of patients identified by the scar-like signature.
View article: Supplementary Figure S2 from Molecular Characterization of Residual Muscle-Invasive Bladder Cancer Identifies a Scar-Like Transcriptomic Profile with Favorable Prognosis after Neoadjuvant Therapy
Supplementary Figure S2 from Molecular Characterization of Residual Muscle-Invasive Bladder Cancer Identifies a Scar-Like Transcriptomic Profile with Favorable Prognosis after Neoadjuvant Therapy Open
Figure S2. Defining novel biological clusters using gene expression profiling in radical cystectomy samples previously treated with neoadjuvant atezolizumab. Signature scores among ABACUS CC1-4 for (A) TGF-beta, (B) FGFR3 pathway, (C) Angi…
View article: Supplementary Figure S1 from Molecular Characterization of Residual Muscle-Invasive Bladder Cancer Identifies a Scar-Like Transcriptomic Profile with Favorable Prognosis after Neoadjuvant Therapy
Supplementary Figure S1 from Molecular Characterization of Residual Muscle-Invasive Bladder Cancer Identifies a Scar-Like Transcriptomic Profile with Favorable Prognosis after Neoadjuvant Therapy Open
Figure S1. Disease Free Survival Outcomes for N = 84 TURBT cases from the ABACUS trial subtyped by Lund (A), Consensus (B) and TCGA (C) subtyping models.
View article: Supplementary Figure S8 from Molecular Characterization of Residual Muscle-Invasive Bladder Cancer Identifies a Scar-Like Transcriptomic Profile with Favorable Prognosis after Neoadjuvant Therapy
Supplementary Figure S8 from Molecular Characterization of Residual Muscle-Invasive Bladder Cancer Identifies a Scar-Like Transcriptomic Profile with Favorable Prognosis after Neoadjuvant Therapy Open
Figure S8. Comparing quantitative immunohistochemistry (IHC) scores between scar-like cases identified by the transcriptomic classifier (TC) and remaining samples from the ABACUS cohort.
View article: Supplementary Figure S3 from Molecular Characterization of Residual Muscle-Invasive Bladder Cancer Identifies a Scar-Like Transcriptomic Profile with Favorable Prognosis after Neoadjuvant Therapy
Supplementary Figure S3 from Molecular Characterization of Residual Muscle-Invasive Bladder Cancer Identifies a Scar-Like Transcriptomic Profile with Favorable Prognosis after Neoadjuvant Therapy Open
Figure S3. Defining novel biological clusters using gene expression profiling in radical cystectomy samples previously treated with neoadjuvant atezolizumab. Gene marker expression scores among ABACUS CC1-4 for (A) KRT5, (B) KRT14, (C) CD4…
View article: Supplementary Table S1 from Molecular Characterization of Residual Muscle-Invasive Bladder Cancer Identifies a Scar-Like Transcriptomic Profile with Favorable Prognosis after Neoadjuvant Therapy
Supplementary Table S1 from Molecular Characterization of Residual Muscle-Invasive Bladder Cancer Identifies a Scar-Like Transcriptomic Profile with Favorable Prognosis after Neoadjuvant Therapy Open
Table S1: Input gene list of the n = 39 gene features included in the scar-like transcriptomic classifier.
View article: In Patients with Muscle-invasive Bladder Cancer Undergoing Radical Cystectomy, Dynamics of Circulating Tumor DNA Following Cystectomy: Association with Patient Outcomes
In Patients with Muscle-invasive Bladder Cancer Undergoing Radical Cystectomy, Dynamics of Circulating Tumor DNA Following Cystectomy: Association with Patient Outcomes Open
Our results highlight that perioperative ctDNA status is associated with patient prognosis in MIBC.
View article: Proteomic profiling identifies muscle-invasive bladder cancers with distinct biology and responses to platinum-based chemotherapy
Proteomic profiling identifies muscle-invasive bladder cancers with distinct biology and responses to platinum-based chemotherapy Open
Platinum-based neoadjuvant chemotherapy prior to radical cystectomy is the preferred treatment for muscle-invasive bladder cancer despite modest survival benefit and significant associated toxicities. Here, we profile the global proteome o…
View article: Histologic subtypes of non-muscle invasive bladder cancer
Histologic subtypes of non-muscle invasive bladder cancer Open
The majority of bladder cancers (BCs) are non-muscle invasive BCs (NMIBCs) and show the morphology of a conventional urothelial carcinoma (UC). Aberrant morphology is rare but can be observed. The classification and characterization of his…
View article: A 2-center review of histopathology of variants of upper urinary tract urothelial carcinoma and their impact on clinical outcomes
A 2-center review of histopathology of variants of upper urinary tract urothelial carcinoma and their impact on clinical outcomes Open
Almost a third of UTUC present VH. Presence of VH is related to more aggressive tumor characteristics and associated with unfavorable outcomes. Due to a higher rate of extravesical recurrences in UTUC with VH, Follow-up controls should inc…
View article: Proteomic profiling identifies muscle-invasive bladder cancers with distinct biology and responses to platinum-based chemotherapy
Proteomic profiling identifies muscle-invasive bladder cancers with distinct biology and responses to platinum-based chemotherapy Open
Platinum-based neoadjuvant chemotherapy (NAC) prior to radical cystectomy is the preferred treatment for muscle-invasive bladder cancer (MIBC) despite modest survival benefit and significant associated toxicities. Here, we profiled the glo…
View article: Diagnostic Value of Urine Cytology in Pharmacologically Forced Diuresis for Upper Tract Urothelial Carcinoma Diagnosis and Follow-Up
Diagnostic Value of Urine Cytology in Pharmacologically Forced Diuresis for Upper Tract Urothelial Carcinoma Diagnosis and Follow-Up Open
We performed a urine cytology analysis of a pharmacologically induced diuresis for the diagnosis of upper tract urothelial carcinoma. To evaluate the diagnostic value of cytology of pharmacologically forced diuresis, an initial cohort of 7…
View article: Diagnostic Value of Urine Cytology in Pharmacologically Forced Diuresis for Diagnosis and Follow-Up of Upper Tract Urothelial Carcinoma
Diagnostic Value of Urine Cytology in Pharmacologically Forced Diuresis for Diagnosis and Follow-Up of Upper Tract Urothelial Carcinoma Open
We performed urine cytology analysis of a pharmacologically induced diuresis for diagnostics of upper tract urothelial carcinoma. To evaluate the diagnostic value of cytology of pharmacologically forced diuresis, a first cohort of 77 conse…
View article: A multicenter review of histopathology of variants in the context of upper urinary tract urothelial carcinoma and their impact on clinical outcomes
A multicenter review of histopathology of variants in the context of upper urinary tract urothelial carcinoma and their impact on clinical outcomes Open
Introduction Similar to bladder cancer, about one third of upper tract urothelial carcinoma (UTUC) present variant histology (VH). We aim to evaluate the incidence, clinical characteristics and the impact on outcomes of VH in UTUC. Methods…
View article: Guidance of adjuvant instillation in intermediate-risk non-muscle invasive bladder cancer by drug screens in patient derived organoids: a single center, open-label, phase II trial
Guidance of adjuvant instillation in intermediate-risk non-muscle invasive bladder cancer by drug screens in patient derived organoids: a single center, open-label, phase II trial Open
Background In intermediate-risk non-muscle invasive bladder cancer (NMIBC) clinical guidelines suggest an adjuvant instillation with a chemotherapeutic agent. However, the agent and regimen are not clearly defined. Worldwide, less than 15%…
View article: Figure S1 from Paternally Expressed Gene 10 (PEG10) Promotes Growth, Invasion, and Survival of Bladder Cancer
Figure S1 from Paternally Expressed Gene 10 (PEG10) Promotes Growth, Invasion, and Survival of Bladder Cancer Open
PEG10 associates with NE markers in bladder cancer.
View article: Data from Selective Inhibition of the Lactate Transporter MCT4 Reduces Growth of Invasive Bladder Cancer
Data from Selective Inhibition of the Lactate Transporter MCT4 Reduces Growth of Invasive Bladder Cancer Open
The significance of lactate transporters has been recognized in various cancer types, but their role in urothelial carcinoma remains mostly unknown. The aim of this study was to investigate the functional importance of the monocarboxylate …
View article: Figure S6 from Paternally Expressed Gene 10 (PEG10) Promotes Growth, Invasion, and Survival of Bladder Cancer
Figure S6 from Paternally Expressed Gene 10 (PEG10) Promotes Growth, Invasion, and Survival of Bladder Cancer Open
PEG10 knockdown attenuates in vivo tumor growth.
View article: Supplementary Data from Selective Inhibition of the Lactate Transporter MCT4 Reduces Growth of Invasive Bladder Cancer
Supplementary Data from Selective Inhibition of the Lactate Transporter MCT4 Reduces Growth of Invasive Bladder Cancer Open
Suppl. Table 1: Characteristics of the TCGA cohort; Suppl. Table 2: Characteristics of cohort A. CIS= carcinoma in situ; Suppl. Table 3: Characteristics of cohort B Suppl. Fig. 1. Correlation of degree of DNA methylation at CpG site cg1018…